PSMA-PET/CT findings were positive in 84% of the patients. PSMA-PET/CT detected distant metastatic disease in 46% of patients, including 34% of patients after RP, 56% after definitive RT, and 60% ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial ... Intravenous; mCRPC: Metastatic castration-resistant prostate cancer; P: Placebo; PSA: Prostate ...

Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel ...

This follows the initial licence for treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in 2020. Following entry into a commercial agreement with Bayer ...

Advancements in targeted therapies have transformed the treatment landscape for NSCLC, enabling precision medicine approaches that improve outcomes. These therapies focus on specific genetic mutations ...

Advanced Imaging Uncovers Hidden Metastases in High-Risk Prostate Cancer Cases ... Allows Rapid Assessment of Ovarian Cancer Subtypes and Their Response to Treatment Dec. 6, 2024 — An MRI ...

However, metastatic ... in the cancer death rate to reductions in smoking; increased uptake in screening for breast, colorectal and prostate cancers; and improvements in cancer treatments.

Keck Medicine of USC is conducting a clinical trial that explores using steam as a potential alternative to surgery or ...

New Mexico Cancer Center’s cutting-edge approach to diagnosing and treating prostate cancer. With a team of dedicated specialists, their personalized treatment plans focus on the most ...

Despite a big increase in “watchful waiting” in the past 15 years, there’s a new study from the U.S. Department of Veterans Affairs health system shows that overtreatment of prostate cancer persists.

TORONTO — Ontario's health minister says the province will now publicly fund a new treatment for advanced-stage prostate ...